{"title":"日本经董事会认证的神经科医生与制药业之间的财务关系","authors":"Anju Murayama, Kenichi Higuchi, Yuki Senoo","doi":"10.1002/ctd2.268","DOIUrl":null,"url":null,"abstract":"<p>This study evaluated the size and fraction of non-research compensation to Japanese board-certified neurologists from the pharmaceutical industry between 2016 and 2020. We found that more than US$45 million were made to 59.2% of all neurologists over the five years. There was an increasing trend in the payments to the neurologists over time.\n\n <figure>\n <div><picture>\n <source></source></picture><p></p>\n </div>\n </figure></p>","PeriodicalId":72605,"journal":{"name":"Clinical and translational discovery","volume":"4 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ctd2.268","citationCount":"0","resultStr":"{\"title\":\"Financial relationships between board-certified neurologists and the pharmaceutical industry in Japan\",\"authors\":\"Anju Murayama, Kenichi Higuchi, Yuki Senoo\",\"doi\":\"10.1002/ctd2.268\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>This study evaluated the size and fraction of non-research compensation to Japanese board-certified neurologists from the pharmaceutical industry between 2016 and 2020. We found that more than US$45 million were made to 59.2% of all neurologists over the five years. There was an increasing trend in the payments to the neurologists over time.\\n\\n <figure>\\n <div><picture>\\n <source></source></picture><p></p>\\n </div>\\n </figure></p>\",\"PeriodicalId\":72605,\"journal\":{\"name\":\"Clinical and translational discovery\",\"volume\":\"4 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ctd2.268\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and translational discovery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/ctd2.268\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and translational discovery","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ctd2.268","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Financial relationships between board-certified neurologists and the pharmaceutical industry in Japan
This study evaluated the size and fraction of non-research compensation to Japanese board-certified neurologists from the pharmaceutical industry between 2016 and 2020. We found that more than US$45 million were made to 59.2% of all neurologists over the five years. There was an increasing trend in the payments to the neurologists over time.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
